Literature DB >> 30742565

Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Kathy Pan1, Linda Diana Bosserman2, Rowan T Chlebowski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30742565     DOI： 10.1200/JCO.18.01360

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.

Authors:  Fabio Conforti; Laura Pala
Journal:  J Clin Oncol       Date:  2019-06-07       Impact factor: 44.544

Review 2.  Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer.

Authors:  Stella D'Oronzo; Erica Silvestris; Angelo Paradiso; Mauro Cives; Marco Tucci
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

Review 3.  Endocrine Therapy in Early Breast Cancer.

Authors:  Katja Krauss; Elmar Stickeler
Journal:  Breast Care (Basel)       Date:  2020-07-21       Impact factor: 2.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.